Sorbonne Université, Centre d'immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Laboratoire de Bactériologie-Hygiène, Assistance Publique-Hôpitaux de Paris (APHP), Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris.
Service de Biologie, Grand Hôpital de l'Est Francilien, Jossigny.
Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1050-1054. doi: 10.5588/ijtld.18.0779.
The World Health Organization (WHO) recommends that multidrug-resistant tuberculosis (MDR-TB) treatment should be managed in collaboration with multidisciplinary advisory committees (consilia). A formal national Consilium has been established in France since 2005 to provide a centralised advisory service for clinicians managing MDR-TB and extensively drug-resistant (XDR-TB) cases. Review the activity of the French TB Consilium since its establishment. Retrospective description and analysis of the activity of the French TB Consilium. Between 2005 and 2016, 786 TB cases or contacts of TB cases were presented at the French TB Consilium, including respectively 42% and 79% of all the MDR-TB and XDR-TB cases notified in France during this period. Treatment regimens including bedaquiline and/or delamanid were recommended for 42% of the cases presented at the French TB Consilium since 2009. Patients were more likely to be presented at the French TB Consilium if they were born in the WHO Europe Region, had XDR-TB, were diagnosed in the Paris region, or had resistance to additional drugs than those defining XDR-TB. The French TB Consilium helped supervise appropriate management of MDR/XDR-TB cases and facilitated implementation of new drugs for MDR/XDR-TB treatment.
世界卫生组织（WHO）建议多药耐药结核病（MDR-TB）的治疗应与多学科咨询委员会（consilia）合作进行管理。自 2005 年以来，法国已经成立了一个正式的国家咨询委员会，为管理 MDR-TB 和广泛耐药（XDR-TB）病例的临床医生提供集中的咨询服务。
回顾法国结核病咨询委员会成立以来的活动。
对法国结核病咨询委员会活动的回顾性描述和分析。2005 年至 2016 年间，法国结核病咨询委员会共介绍了 786 例结核病病例或结核病病例接触者，其中分别包括该期间法国报告的所有 MDR-TB 和 XDR-TB 病例的 42%和 79%。自 2009 年以来，法国结核病咨询委员会建议为 42%在该委员会介绍的病例使用包含贝达喹啉和/或德拉马尼的治疗方案。
如果患者出生于世卫组织欧洲区域、患有 XDR-TB、在巴黎地区诊断或对除定义为 XDR-TB 的药物之外的其他药物具有耐药性，则更有可能将其介绍给法国结核病咨询委员会。法国结核病咨询委员会有助于监督 MDR/XDR-TB 病例的适当管理，并促进 MDR/XDR-TB 治疗新药的实施。
